Research progress on palmitoylation of postsynaptic density protein 95 / 中华老年医学杂志

Postsynaptic density protein 95(PSD-95) ,the most abundant and significant synapse scaffolding protein at excitatory synapses ,is a hallmark of synaptic function. Proteins palmitoylation is one of the important post-translational modifications ,which is occurred more frequently in the nervous system than in other organs. Palmitoylation-dependent regulation of PSD-95 has become a research hotspot in the fields of neuroplasticity and neuropsychiatric diseases.

Comparison of social function， adverse reaction and medication adherence of Paliperidone， Amisulpride and Olanzapine in patients with first-episode schizophrenia / 中国医师杂志

Objective To investigate the social function, adverse reaction and medication adherence of paliperidone, amisulpride, and olanzapine in patients with first episode schizophrenia.Methods A total of 96 patients with first episode of schizophrenia was randomly divided into three groups, with reference to random numbers, among which there were 32 in paliperidone group, 32 cases in amisulpride group, and 32 in olanzapine group.All the patients in all groups were assessed with negative and positive scale (PANSS), personal and social performance scale (PSP), drug attitude inventory (DAI) at baseline and the end of 6 months.Results (1) There was no significant difference in the therapeutic effect between three groups (P ＞ 0.05);(2) The scores of PSP and DAI were increased in three groups after treatment, and the difference was statistically significant compared to that before treatment (P ＜ 0.05).Conclusions Three drugs have similar efficacy in the treatment of first-episode schizophrenia, and there is no significant difference in improving medication compliance and social function.

Síntesis y evaluación in vitro de la actividad antifúngica de oximas, éteres de oxima e isoxazoles / Síntese e avaliação in vitro da atividade antifúngica de oximas, éteres de oxima e isoxazóis / Synthesis and in vitro assessment of antifungal activity of oximes, oxime ethers and isoxazoles

Objetivo. Sintetizar y realizar la evaluación preliminar de la actividad antifúngica in vitro de oximas, éteres de oxima e isoxazoles. Materiales y métodos. Las oximas se sintetizaron a partir de aldehídos o cetonas con NH2OH.HCl y K2CO3. Los éteres de oxima se obtuvieron mediante alquilación de oximas con bromuro de propargilo o bromuro de 2-bromobencilo, empleando como base NaOH y acetona como solvente. Los isoxazoles se obtuvieron mediante cicloadiciones 1,3-dipolares empleando nitrato cérico amónico (NAC), cloramina-T (CAT) y NaOCl. Los productos fueron identificados y/o caracterizados por resonancia magnética nuclear (RMN) y espectrometría de masas (EM). Se realizaron pruebas de inhibición de crecimiento radial sobre Aspergillus niger y Fusarium roseum. Resultados. Se obtuvieron cinco oximas, siete éteres de oxima, cuatro de ellos nuevos y cuatro nuevos isoxazoles. Las sustancias evaluadas presentaron actividad antifúngica a cantidades de 1,5 mg y 3,0 mg. Conclusiones. Aunque las cicloadiciones 1,3-dipolares permitieron obtener los isoxazoles esperados, se observó que ésta metodología generó una amplia variedad de subproductos lo que disminuyó los rendimientos e hizo difícil la purificación del producto de interés. Cuatro de las sustancias evaluadas presentaron porcentajes de inhibición superiores al 80%...

Synthesis and in vitro assessment of antifungal activity of oximes, oxime ethers and isoxazoles. Objective. To synthesize and carry out a preliminary evaluation of the in vitro antifungal activity of oximes, oxime ethers and isoxazoles. Materials and methods. Oximes were synthesized from aldehydes or ketones with NH2OH.HCl and K2CO3. Oxime ethers were prepared by alkylation of oximes with propargyl bromide or 2-bromobenzyl bromide, using NaOH as base and acetone as solvent. The isoxazoles were obtained by 1,3-dipolar cycloadditions using ceric ammonium nitrate (CAN), chloramine T (CAT) and NaOCl. Products were identified or characterized using nuclear magnetic resonance (NMR) and mass spectrometry (MS). Radial growth inhibition assays against Aspergillus niger and Fusarium roseum were carried out. Results. Five oximes, seven oxime ethers, four of them new, and four new isoxazoles were obtained. The assessed substances exhibited antifungal activity in amounts of 1,5 mg and 3,0 mg. Conclusions. Although 1,3-dipolar cycloadditions allowed to obtain the desired isoxazoles, this methodology produced a wide variety of side products that reduced yields and made difficult the purification of the target products. Four of the tested compounds showed inhibition percentages greater than 80%...

Síntese e avaliação “in vitro” da atividade antifúngica de oximas, éteres de oxima e isoxazóis. Objetivo. Sintetizar e realizar a avaliação preliminar da atividade antifúngica in vitro de oximas, éteres de oxima e isoxazóis. Materiais e métodos. As oximas foram sintetizadas a partir de aldeídos ou cetonas com NH2OH.HCl e K2CO3. Os éteres de oxima foram obtidos pela alquilação de oximas com brometo de propargilo ou brometo de 2-bromobenzilo, utilizando NaOH como base e acetona como solvente. Os isoxazóis foram obtidos por cicloadição 1,3-dipolar usando nitrato cérico de amônio (NCA), cloramina-T (CAT) e NaOCl. Os produtos foram identificados e / ou caracterizados por ressonância magnética nuclear (RMN) e espectrometria de massas (EM). Foram realizados testes de inibição sobre o crescimento radial de Aspergillus niger e Fusarium roseum. Resultados. Foram obtidas cinco oximas, sete éteres de oxima, quatro deles novos e quatro novos isoxazóis. As substâncias testadas apresentaram atividade antifúngica em quantidades de 1,5 mg e 3,0 mg. Conclusões. Embora as cicloadições 1,3-dipolares permitiram obter os isoxazóis esperados, observou-se que esta metodologia resultou numa grande variedade de subprodutos que reduziram os rendimentos e tornaram difícil a purificação do produto de interesse. Quatro das substâncias testadas apresentaram porcentagens de inibição acima de 80%...

A randomized,double-blind,placebo-controlled,multicenter study to evaluate the efficacy and safety of zonisamide as adjunctive treatment in patients with refractory partial seizures / 中华神经科杂志

Objective To evaluate the safety and efficacy of Zonisamide(ZNS) as adjunctive therapy in patients with refractory partial seizures receiving other antiepileptic drags (AEDs).Methods This was a randomized,double-blind,placebo-controlled study conducted at multi-centers.All 240 subjects were randomized to either the ZNS group or the placebo group in a 1:1 ratio.The double-blind treatment phase included a titration phase during which zonisamide dose inereased from 100 mg/day to 300 mg/day over 4 weeks and then a 12-week fixed-dose phase.The primary efficacy endpoint was,the median % reduction from baseline in all pattial seizure frequency(CPS+SPS+SGS)during the fixed-dose phase.The important secondaw endpoint wag the responder rate.Safety profiles and tolerance were also evaluated.Results The FAS analysis showed the median reduction from baseline in the ZNS group was greater than in the placebo group(48.4%vs 26.6%),the difference was significant for ZNS compared with placebo(F=4.904,P=0.028);The responder rates for all partial seizures(48.6%vs34.9%,X2=4.046,P=0.044)and for complex seizures(52.2% vs 33.3%,X2=5.607,P=0.018)were significantly higber in the ZNS group than in the placebo group in the FAS population.The overall adverse events(AEs)profile was comparable between the two groups.The most frequent AEs considered to be related to zonisamide by the investigator were headache,dizziness,somnolence,anorexia,nausea,etc.Conclusions ZNS is superior to placebo in reducing the frequency of partial seizures and well-tolerated.ZNS could be a choice of adjunctive therapy in patients with refractory partial seizures.

Multicenter randomized, double-blind, placebo-controlled trial of zonisamide as add-on therapy in patients with refractor partial seizures / 中华神经科杂志

Objective To evaluate the efficacy and tolerability of zonisamide (ZNS) as add-on therapy in patients with refractory partial seizures.Methods In this Chinese muiticenter, double-blind, randomized, placebo-contrclled trial, ZNS was compared with placebo add-on therapy in 217 patients (intent-to treat (ITT) population) with uncontrolled partial-onset seizures.All patients entered a 3-month baseline period followed by a 4-week titration interval and a 12-week maintenance period.The starting dose of ZNS group was 100 mg/d, increased by 100 mg/d every week and reached the goal of 400 mg/d.The main outcome was measured by the median of the percentage of decreased seizure frequency.The secondary ouwomes points included the percentage of patients who had seizure attacks decreased by more than 50%,and adverse events.Results The median of the percentage of decreased seizure frequency in ZNS group was 33.33%, and the placebo group was 0.Thirty-eight patients (34.23%) experienced more than 50% reduction in the seizure frequency in ZNS group, compared with 19.81% of patients (21 cases) in the placebo group (χ2 =5.7159,P =0.0168) ; Moreover, 13 (11.71%) patients in ZNS group and 5 patients in placebo group were seizure free, 25 patients in ZNS group and 16 patients in placebo group who had seizure attacks decreased by more than 50%.The availability rate in ZNS group was higher than placebo group (34.23% vs 19.81%, U=2.4701, P=0.0135).The most common adverse events in ZNS group were drowsiness, fatigue, decreased appetite, gastrointestinal complaints, insomnia and constipation.Conclusion Zonisamide treatment was generally well tolerated and was associated with significant reductions in seizure frequency as adjunctive treatment for partial-onset seizures.